Evaluation of the curative and preventive efficacy of a single oral administration of afoxolaner against cat flea Ctenocephalides felis infestations on dogs  by Hunter, James S. et al.
E
o
C
J
J
a
b
c
d
K
C
F
D
A
C
1
i
0
lVeterinary Parasitology 201 (2014) 207–211
Contents lists available at ScienceDirect
Veterinary  Parasitology
jo u r nal homep age: www.elsev ier .com/ locate /vetpar
valuation  of  the  curative  and  preventive  efﬁcacy  of  a  single
ral  administration  of  afoxolaner  against  cat  ﬂea
tenocephalides  felis  infestations  on  dogs
ames  S.  Hunter  III a,  Pascal  Dumontb, Theodore  S.  Chestera,  David  R.  Youngc,
osephus  J.  Fouried,  Diane  L.  Larsena,∗
Merial Limited, 3239 Satellite Boulevard, Duluth, GA 30096, USA
Merial SAS, 29 Avenue Tony Garnier, 69007 Lyon, France
Young Veterinary Research Services, 7243 East Avenue, Turlock, CA 95380, USA
ClinVet International, Universitas 9301, Bloemfontein, Free State, South Africa
a  r  t  i  c  l  e  i  n  f  o
eywords:
tenocephalides felis
leas
ogs
foxolaner
urative and prophylactic efﬁcacy
a  b  s  t  r  a  c  t
The  efﬁcacy  of orally  administered  afoxolaner  for treatment  and  prevention  of  repeated
infestations  with  adult  Ctenocephalides  felis  on  dogs  was  evaluated  in  two  studies  after
administration  of a beef-ﬂavored  soft  chew. In  each  study,  32 dogs  were  divided  randomly
into  four  equal  groups.  Dogs  in Groups  1 and  3 were  not  treated  and  served  as controls.
Dogs  in Groups  2 and  4  were  treated  on Day  0 with  a  combination  of  chewable  tablets  to
be as  close  as  possible  to  the  minimum  therapeutic  dose  of 2.5 mg/kg.  All animals  were
infested  experimentally  with  unfed  C.  felis  (100  ± 5)  on  Days  −1, 7,  14, 21,  28  and 35. Flea
killing  efﬁcacy  was  evaluated  in  both  studies  while,  efﬁcacy  against  ﬂea  egg  production
was  assessed  in Study  1. Live ﬂeas  were  counted  at 12  (Groups  1 and  2) and  24  h  (Groups
3  and  4),  after  treatment  or after  weekly  infestations.  In Study  1, ﬂea  eggs  were collected
and  counted  at either  12  or 24  h  after  each  ﬂea  infestation  on Days  7, 14,  21,  28  and  35.  The
results  of  both  studies  demonstrate  the long  lasting  and  rapid  efﬁcacy  of  afoxolaner  against
C.  felis, when  administered  as  a single  oral  dose  to  dogs.  For  ﬂea  counts  conducted  24  h  after
treatment  or  infestation,  efﬁcacy  was  100%  for all time  points  up  to Day  36  in  both  studies,
except  for  one  time  point  (99.9%  on  Day  22) for Study  2.  For  ﬂea  counts  performed  12  h
after  treatment  or infestation,  efﬁcacy  was ≥95.2%  until  Day  21  in  both  studies.  Efﬁcacy  at
12 h was  ≥93.0%  on Day  35 in Study  1 and  ≥89.7%  on  Day  35  in Study  2. The  treated groups
had  signiﬁcantly  fewer  ﬂeas  than  untreated  control  dogs  in both  studies  for  all ﬂea  counts
(p  =  0.003  Study  1, p = 0.0006  Study  2). In Study  1,  for all  egg  counts  performed  at or beyond
Day  7, efﬁcacy  in egg  reduction  was  >99%  for  all time  points  between  Days  7 and  35.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. IntroductionEctoparasitoses account for the most frequent diseases
n carnivores worldwide with ﬂeas and ticks representing
∗ Corresponding author.
http://dx.doi.org/10.1016/j.vetpar.2014.02.024
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icenses/by-nc-nd/3.0/).the most prevalent parasites (Beugnet and Franc, 2012;
Otranto et al., 2009a, b). The cat ﬂea, Ctenocephalides felis, is
the main ﬂea species infesting both dogs and cats (Dryden
and Rust, 1994; Rust and Dryden, 1997). In addition to caus-
ing annoyance and discomfort to pets and their owners, cat
ﬂeas are associated with several diseases. C. felis is primarily
responsible for ﬂea bite allergy dermatitis (FAD) in dogs and
ss article under the CC BY-NC-ND license (http://creativecommons.org/
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cats (Dryden and Blakemore, 1989; Plant, 1991; Carlotti
and Costargent, 1994) as a result of hypersensitivity to
components of ﬂea saliva (Dryden and Rust, 1994; Stopler,
1994). The cat ﬂea is also the primary intermediate host
of the tapeworm Dipylidium caninum, the common intesti-
nal cestode of dogs and cats (Dunn, 1978; Pugh, 1987). C.
felis can also transmit murine typhus, Rickettsia felis, and
has been implicated in the transmission of some Bartonella
species, such as B. henselae, the agent of Cat Scratch Disease
(Azad et al., 1997; Orloski and Lathrop, 2003; Just et al.,
2008).
Although the use of insecticides such as ﬁpronil, imida-
cloprid, selamectin, and spinosad has revolutionized ﬂea
control in recent years, treatment and prevention of cat
ﬂea infestations remain a major concern for pet owners
and veterinarians (Beugnet and Franc, 2012; Rust, 2005).
New compounds that are fast acting, long lasting, and easy
to administer are needed to complement the existing prod-
ucts on the market. This paper demonstrates the efﬁcacy of
orally administered afoxolaner, a newly identiﬁed isoxazo-
line insecticide–acaricide molecule (Letendre et al., 2014;
Shoop et al., 2014) against C. felis in dogs.
2. Materials and methods
2.1. Animals
Both studies were conducted with thirty-two healthy
beagles of both sexes. The dogs in Study 1 included twenty-
two males and ten females over twelve months of age
which weighed between 9.1 and 19.1 kg. The dogs allocated
to Study 2 were twelve males and twenty females over 6
months of age which weighed between 8.2 kg and 19.6 kg.
The protocol of the studies was reviewed and approved
by the Merial Institutional Animal Care and Use Commit-
tee. Dogs were handled with due regard for their welfare
(USDA, 2008). All animals were housed individually. All
dogs received commercial food, once daily, in a sufﬁcient
amount to maintain a healthy physical state, and water
was provided ad libitum.  The dogs were not treated with
ectoparasiticides (either topical or systemic) within three
months prior to the start of the study. Dogs enrolled in the
studies underwent a full physical examination by a veteri-
narian on Day −7 and were examined once daily for health
observations.
2.2. Experimental study designs
The study designs were in accordance with the World
Association for the Advancement of Veterinary Parasitol-
ogy (WAAVP) guidelines for evaluating the efﬁcacy of
parasiticides for the treatment, prevention and control of
ﬂea and tick infestation on dogs and cats (Marchiondo et al.,
2013), and was  conducted in accordance with Good Clinical
Practices, (VICH guideline GL9) (EMEA, 2000).
The studies were blinded, negative-controlled clinical
efﬁcacy studies, utilizing a block design based on Day −6
ﬂea counts. In each study, dogs were infested with 100
(±5) unfed adult C. felis on Day −7, which were removed
and counted on Day −6. The C. felis strain used for infes-
tations in Study 1 was a U.S. strain of ﬂeas that has beenitology 201 (2014) 207–211
maintained for approximately 11 years from wild ﬂeas
captured in California. In Study 2, a ﬂea strain that origi-
nated from Hanover University, Germany, was used. The
experimental study unit was the individual dog, which
was  identiﬁed, treated and assessed on an individual basis.
In each study, the 32 dogs were allocated to 8 blocks of
4 animals each. Within each block, the dogs were ran-
domly assigned to one of the 2 counting time-by-treatment
combinations (i.e., control 12-h (Groups 1), treated 12-
h (Groups 2), control 24-h (Groups 3) and treated 24-h
(Groups 4).
In each study, dogs were infested with 100 (±5) unfed
adult C. felis once on Days −1, 7, 14, 21, 28 and 35.
Fleas were removed, counted and categorized as dead/alive
12 h ± 30 min  after treatment or challenge infestation for
Groups 1 and 2 and 24 ± 1 h after treatment or challenge
infestation for treatment Groups 3 and 4. Each dog was
combed for a minimum of 10 min  using a ﬁne-toothed ﬂea
comb. If ﬂeas were found during these 10 minutes, then
the dog was  combed for 15 min. However, if no ﬂeas were
found on the dog in these 10 min, then the combing was
stopped (Marchiondo et al., 2013). The personnel perform-
ing comb counts and caring for the animals were blinded
to all treatment group allocations.
In addition in Study 1, collections of ﬂea eggs were also
performed on Days 7, 14, 28 and 35 (at +12 h and +24 h).
The waste pans below the cages were cleaned, and the
pans were lined with paper that facilitated the collection
of ﬂea eggs. The shed ﬂea eggs were collected and counted
at 12 h ± 30 min  post infestation for Groups 1 and 2 and at
24 ± 1 hour post infestation for Groups 3 and 4. Debris was
sifted in a 30-mesh strainer and the eggs were retained.
Collected eggs were counted and recorded.
In Study 1, any remaining food was removed from the
dogs in the afternoon of Day −1, and dogs were not fed
prior to treatment on Day 0, whereas in Study 2, dogs were
either offered their normal ration prior to treatment or
immediately following treatment on Day 0. In both stud-
ies, dogs in Groups 1 and 3 remained untreated and served
as controls. In both studies, dogs in Groups 2 and 4 were
dosed once orally with the appropriate soft chew formu-
lations containing afoxolaner. Four sizes of chews were
available: 0.5 g, 1.25 g, 3 g and 6 g, containing, respectively,
11.3 mg,  28.3 mg,  68 mg  and 136 mg  of afoxolaner. The dose
range was 2.5–3.1 mg/kg in Study 1 (mean = 2.76 mg/kg in
Group 2 and 2.83 mg/kg in Group 4) and 2.5–2.8 mg/kg in
Study 2 (mean = 2.63 mg/kg in Group 2 and 2.66 mg/kg in
Group 4) using a combination of the chews in order to
be as close as possible to the minimum therapeutic dose
of 2.5 mg/kg. Dogs were observed prior to treatment and
hourly (±30 min) for 4 h post-treatment.
2.3. Data analysis
The ﬂea counts were transformed to the natural log-
arithm of (count +1) for calculation of geometric means
by treatment group at each time point. Percent efﬁcacy
of the treated group with respect to the control group
was  calculated using the formula [(C − T)/C] × 100, where
C = geometric mean for the control group and T = geometric
mean for the treated group for each time point.
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The log-counts of the treated group were compared to
he log-counts of the untreated control group using an F-
est adjusted for the allocation blocks used to randomize
he animals to the treatment groups at each time point
eparately. The mixed procedure in SAS® version 9.1.3 was
sed for the analysis with treatment group listed as a ﬁxed
ffect and the allocation blocks listed as a random effect.
ll comparisons were made using the (two-sided) 5% sig-
iﬁcance level.
The egg counts at each time point were transformed
o the natural logarithm of (count +1) for calculation
f geometric means by treatment group at each time
oint. Percent efﬁcacy of the treated group with respect
o the control group was calculated using the formula
(C − T)/C] × 100, where C = geometric mean for the control
roup and T = geometric mean for the treated group.
The log-counts of the two groups were compared using
he mixed procedure in SAS® version 9.1.3 with treatment
s the ﬁxed effect and allocation block the random effect.
 two-sided 5% signiﬁcance level was used.
. Results
.1. Flea counts
The ﬂea counts for both studies are summarized in
able 1. In both studies, the ﬂea counts of untreated dogs
ere consistently high, with geometric means ranging
rom 58.9 to 93.8.
For live ﬂea counts performed 12 h after treatment or
hallenge infestations, the percent efﬁcacy was ≥95.2% for
he ﬁrst four infestations through Day 21, was 81.1% on Day
8, and was 93% on Day 35 in Study 1. Efﬁcacy at 12 h was
98.5% through Day 28 and 89.7% on Day 35 for Study 2.
For live ﬂea counts performed 24 h after treatment or
hallenge infestations, percent efﬁcacy was 100% for all
ime points until Day 35, with the exception of one time
oint (99.9% on Day 22) for Study 2. The ﬂea counts were
igniﬁcantly different between treated and control dogs at
ll time-points for both 12 and 24 h counts in both studies
p = 0.003 Study 1, p = 0.0006 Study 2).
.2. Eggs counts
The ﬂea egg counts for Study 1 are summarized in
able 2.
For egg counts performed 12 h after treatment, meaning
6 h after ﬂea infestations, 22 eggs were found from treated
ogs (Groups 2, 0–11 eggs per dog) and a total of 183 eggs
rom control dogs (Groups 1, 4–90 eggs per dog) (efﬁcacy of
8.8%, p < 0.004). For egg count performed 24 h after treat-
ent, meaning 48 h after ﬂea infestations, 43 eggs were
ound from treated dogs (Groups 4, 1–17 eggs per dog) and
 total of 431 eggs from control dogs (0–118 eggs per dog)
efﬁcacy of 85.8%, p = 0.028).
For egg counts performed 12 h after infestation at or
eyond Day 7, two treated animals had a single egg col-
ected on Day 14, compared to 216 eggs collected in Group
 dogs (9–62 eggs per dog), resulting in 99.1% efﬁcacy. One
reated animal had a single egg collected on Day 21, com-
ared to 213 eggs collected in Group 1 dogs (3–81 eggs per Ta
b
le
 
1
Ef
ﬁ
ca
cy
 
of
 
af
o
Ti
m
ea
p
os
t-
in
fe
st
12
24
a
Ti
m
e 
(i
n
 
210 J.S. Hunter III et al. / Veterinary Parasitology 201 (2014) 207–211
Table  2
Efﬁcacy of afoxolaner soft chew (2.5 mg/kg) treatment against ﬂea egg production after challenge with ﬂeas for 5 weeks.
Time post-infestationa
(h)
Day of infestation
post-treatment
Geometric mean egg
counts Group 1 or 3
(n  = 8) untreated
control
Geometric mean egg
counts Group 2 or 4
(n = 8) afoxolaner
Percent
efﬁcacy
p-Value
12 7 13.4 0.0 100.0 <0.001
14  21.7 0.2 99.1 <0.001
21 18.8 0.1 99.5 <0.001
28 20.1 0.0 100.0 <0.001
35  10.7 0.0 100.0 <0.001
24 7  25.5 0.0 100.0 <0.001
14  39.7 0.1 99.8 <0.001
21  38.5 0.0 100.0 <0.001
unted.28  22.8 
35  16.7 
a Time (in h) after infestation that the ﬂeas eggs were collected to be co
dog) resulting in 99.5% efﬁcacy. No eggs were collected on
treated dogs at Days 7, 28 or 35, when 150, 194 and 112
eggs were collected from control dogs at Days 7, 28 and 35,
respectively.
For C. felis egg counts performed 24 h after challenge
infestation at or beyond Day 7, only one treated animal had
a single egg collected on Day 15, compared to 438 eggs col-
lected from control dogs (8–113 eggs per dog), resulting
in 99.8% efﬁcacy. For all other time points at 24 h post-
infestation, the efﬁcacy was 100% as no eggs were found in
the treated Group. In the control group, 297, 421, 253 and
357 eggs were collected at Days 8, 22, 29 and 36, respec-
tively.
There was no observed adverse event based on hourly
post-treatment observations for 4 h and daily observations
thereafter.
4. Discussion
Oral treatment of dogs with the new insecticide afox-
olaner at the minimum effective dose of 2.5 mg/kg provided
≥99.9% efﬁcacy against adult ﬂeas at 24 h count for 5 weeks
after a single administration.
The present study also demonstrated a sustained 12 h
efﬁcacy against adult ﬂeas for a full month. The results
of additional efﬁcacy studies (Kunkle et al., 2014) demon-
strated the excellent activity of afoxolaner against the dog
ﬂea Ctenocephalides canis (Dumont, 2014).
In addition, the results of ﬂea egg counts demonstrated
that one treatment reduced egg production by 99.1–100%
as early as 12 and 24 h after infestation for up to 5 weeks.
The ability to block egg production is an especially
important consideration since adult female C. felis can lay
an average of 20–30 eggs a day (Guaguère and Beugnet,
2008). Thus, the regular use of afoxolaner may  potentially
reduce household contamination by ﬂea eggs and, conse-
quently, the ﬂea biomass in the environment.
Interestingly, according to the design of the present
study, the presence of ﬂea eggs in the control group was
uncertain since it is usually accepted that female ﬂeas
start laying eggs on average 36 h after the host infestation
(Dryden and Rust, 1994). Nevertheless, a sufﬁcient eggs
production was obtained in the control group as early as
12 h (112–213 eggs) and 24 h (253–421 eggs) after each0.0 100.0 <0.001
0.0 100.0 <0.001
infestation. This early egg laying may  be related to poten-
tial reproductive speciﬁcity of the C. felis strain used for
infestations. Nevertheless, a similar early egg production
was  obtained with a C. canis ﬂea strain in another study
(Dumont, 2014). It rather suggests that some females in
any ﬂea populations may  start to lay eggs sooner after host
infestation than previously assumed. This later character-
istic underlines the need for insecticides with a sufﬁcient
speed of action allowing the killing of ﬂeas before they start
laying eggs. Alternatively the combination of an IGR (Insect
Growth Regulator) with the insecticide will prevent the
development of immature ﬂea stages (Beugnet et al., 2012).
In conclusion, these studies conﬁrm the excellent efﬁ-
cacy of a single treatment of afoxolaner in beef-ﬂavored
soft chews against C. felis and also provide evidence that
monthly treatments with afoxolaner can prevent C. felis
infestations by killing the adults before egg production
starts.
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